Table 2.
Relationships between gamma oscillatory biomarkers and TCT-related change in cognitive and clinical outcomes.
| TCT R2 | TAU R2 | ASSR × treatment interaction | |||||
|---|---|---|---|---|---|---|---|
| ΔR2 | β | SE | t | p | |||
| Baseline gamma power | |||||||
| Δ MCCB-NC | 0.31 | 0.06 | 0.16 | 0.40 | 0.15 | 2.64 | 0.012 |
| Δ SANS composite | 0.03 | 0.01 | 0.02 | –0.15 | 0.17 | –0.87 | 0.390 |
| Δ SAPS composite | 0.16 | 0.00 | 0.00 | –0.06 | 0.16 | –0.39 | 0.699 |
| Baseline gamma phase-locking | |||||||
| Δ MCCB-NC | 0.15 | 0.05 | 0.08 | 0.30 | 0.16 | 1.83 | 0.075 |
| Δ SANS composite | 0.02 | 0.01 | 0.01 | –0.13 | 0.18 | –0.73 | 0.473 |
| Δ SAPS composite | 0.09 | 0.02 | 0.00 | –0.06 | 0.16 | –0.38 | 0.703 |
| 1-h Δ Gamma power | |||||||
| Δ MCCB-NC | 0.19 | 0.01 | 0.07 | –0.26 | 0.16 | –1.62 | 0.115 |
| Δ SANS composite | 0.30 | 0.04 | 0.15 | –0.39 | 0.15 | –2.53 | 0.016 |
| Δ SAPS composite | 0.40 | 0.04 | 0.14 | 0.38 | 0.15 | 2.59 | 0.014 |
| 1-h Δ Gamma phase locking | |||||||
| Δ MCCB-NC | 0.00 | 0.06 | 0.02 | 0.14 | 0.17 | 0.86 | 0.396 |
| Δ SANS composite | 0.20 | 0.15 | 0.00 | –0.03 | 0.16 | –0.16 | 0.871 |
| Δ SAPS composite | 0.20 | 0.24 | 0.24 | 0.50 | 0.14 | 3.52 | 0.001 |
The primary analysis focused on elucidating significant ASSR biomarker × treatment interactions on TCT-related change in cognitive and clinical outcomes using linear regressions. To further clarify any significant interactions, R2 values are also provided for linear regressions run in TCT and TAU groups, separately.